Do cancer cells selectively mutate HFE to increase their intracellular iron?

Oncology Reports

Volumn 14, Issue 2, 2005, Pages 299-303

  Müller, Claudia I ^a   Miller, Carl W ^a   Kawabata, Hiroshi ^b   McKenna Jr , Robert I ^a   Marchevsky, Alberto M ^a   Koeffler, H Phillip ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cancer cells; Growth advantage; HFE; Iron uptake; Mutations; TfR

Indexed keywords

DNA; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; IRON; MEMBRANE PROTEIN; MICROSATELLITE DNA;

ARTICLE; CELL STRAIN HCT116; CELL STRAIN HL 60; CELL STRAIN HT29; CHEMISTRY; CHROMOSOME 6; GENETICS; HELA CELL; HETEROZYGOSITY LOSS; HUMAN; INTRACELLULAR SPACE; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MISSENSE MUTATION; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR CELL LINE;

BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 6; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HCT116 CELLS; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HL-60 CELLS; HT29 CELLS; HUMANS; INTRACELLULAR SPACE; IRON; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICROSATELLITE REPEATS; MUTATION; MUTATION, MISSENSE; NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 24744453101     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.2.299     Document Type: Article

References (18)

1. Neckers LM: Regulation of transferrin receptor expression and control of cell growth. Pathobiology 59: 11-18, 1991.
2. Cazzola M, Bergamanschi G, Dezza L, Ponchio L, Rosti V, Zappone E and Ascari E; Role of iron and proteins of iron metabolism in cell growth. Curr Stud Hematol Blood Transf 58: 153-157, 1991.
3. Yang S-P, Song S-T and Song H-F: Advancements of antisense oligonucleotides in treatment of breast cancer. Acta Pharmacol Sin 24: 289-295, 2003. (Pubitemid 36402190)
4. Reichard P and Ehrenberg A: Ribonucleotide reductase - a radical enzyme. Science 221: 514-519, 1983.
5. Reizenstein P: Iron, free radicals and cancer. Med Oncol Tumor Pharmacother 8: 229-233, 1991.
6. Gavanaugh PG, Jia L, Zou Y and Nicolson GL: Transferrin receptor overexpression enhances transferring responsiveness and the metastatic growth of a rat mammary adenocarcinoma cell line. Breast Cancer Res Treat 56: 203-217, 1999. (Pubitemid 29495652)
7. Feder JN, Gnirke A, Thomas W, et al: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13: 399-408, 1996. (Pubitemid 26256612)
8. Camaschella C, Roetto A and De Gobbi M: Genetic haemochromatosis: genes and mutations associated with iron loading. Best Practice Res Clin Haematol 15: 261-276, 2002.
9. Salter-Cid L, Brunmark A, Peterson PA and Yang Y: The major histocompatibility complex-encoded class I-like HFE abrogates endocytosis of transferrin receptor by inducing receptor phosphorylation. Genes Immun 1: 409-417, 2000.
10. Feeney GP and Worwood M: The effects of wild-type and mutant HFE expression upon cellular iron uptake in transfected human embryonic kidney cells. Biochim Biophys Acta 1538: 242-251, 2001. (Pubitemid 32402247)
11. Xie D, Hofmann WK, Mori N, Miller CW, Hoelzer D and Koeffler HP: Allelotype analysis of the myelodysplastic syndrome. Leukemia 14: 805-810, 2000. (Pubitemid 30235056)
12. Boldt DH: New perspectives in iron: an introduction. Am J Med Sci 318: 207-212, 1999.
13. Kallianpur AR, Hall LD, Yadav M, et al: Increased prevalence of the HFE C282Y hemochromatosis alleles in women with breast cancer. Cancer Epidemiol Biomarkers Prev 13: 205-212 2004. (Pubitemid 38222550)
14. Parkilla S, Niemelä O, Britton RS, Fleming RE, Waheed A, Bacon BR and Sly WS: Molecular aspects of iron absorption and HFE expression. Gastroenterology 121: 1489-1496, 2001. (Pubitemid 33140466)
15. Cazzola M, Bargamanschi G, Deazza L and Arosio P: Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 75: 1903-1919, 1990. (Pubitemid 20180277)
16. Simonart T, Boelaert JR, Mosselmans R, Andrei G, Noel JC, De Clercq ED and Snoeck R: Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells. Gynecol Oncol 85: 95-102, 2002. (Pubitemid 34304016)
17. Jiang XP, Wang F, Yang DC, Elliott RL and Head JF: Induction of apoptosis by iron depletion in the human breast cancer MCF-7 cell line and the 13762NF rat mammary adenocarcinoma in vivo. Anticancer Res 22: 2685-2692, 2002. (Pubitemid 36069298)
18. Bomford A and Williams R: Long term results of venesection therapy in idiopathic hemochromatosis. Q J Med 45: 611-623, 1976.